Key result
Oral monotherapy for pulmonary arterial hypertension may still benefit select patients despite the proven benefits of up-front or sequential combination therapy regimens.
Why the study?
Does oral monotherapy remain beneficial compared to combination therapy in patients with pulmonary arterial hypertension?
Does oral monotherapy remain beneficial compared to combination therapy in patients with pulmonary arterial hypertension?
This review highlights that despite the shift towards combination therapy in PAH, oral monotherapy may still have a role for select patients.
Answers are grounded in this paper and cite their sources.
Supports individualized monotherapy for select PAH patients; leaves open optimal responder identification in future trials.
Over the past 20 years, pulmonary arterial hypertension management has evolved dramatically, with development and approval of more than a dozen drugs targeted at 3 cellular pathways. Recent trials, including patients either already on background therapy or up-front combination regimens have shown benefits of combination therapy. However, some patients in these recent trials and in practice seem to benefit from a single drug approach. The role of monotherapy in PAH is reviewed in this paper.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2017) conducted a review in Pulmonary arterial hypertension. Oral monotherapy vs. Combination therapy was evaluated. Oral monotherapy for pulmonary arterial hypertension may still benefit select patients despite the proven benefits of up-front or sequential combination therapy regimens.
Synapse has enriched 10 related papers. Consider them for comparative context: